Payment overview · 2025
General Payments
$512.85
35 reported records · 9 companies
Healthcare provider profile · identity verified
Elsayed A Sahloul, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hepatology · HAZLET, NJ · NPI 1467452565
Verified facts
What the public records show
CMS Open Payments records show Elsayed A Sahloul, MD received $512.85 in general payments during 2025 across 35 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $179.44 | 35.0% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $142.74 | 27.8% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.85 | 9.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.24 | 7.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.91 | 6.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.25 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.75 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.00 | 3.1% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $13.67 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $512.85 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $179.44 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $142.74 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 253 | 63 |
| Metformin Hcl | Metformin Hcl | 174 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 45 |
| Montelukast Sodium | Montelukast Sodium | 143 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 106 | 23 |
| Eliquis | Apixaban | 105 | 27 |
| Losartan Potassium | Losartan Potassium | 103 | 32 |
| Alprazolam | Alprazolam | 102 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 33 |
| Tramadol Hcl | Tramadol Hcl | 94 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 24 |
| Gabapentin | Gabapentin | 89 | 25 |
| Furosemide | Furosemide | 79 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 33 |
| Azithromycin | Azithromycin | 73 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 16 |
| Lisinopril | Lisinopril | 71 | 22 |
| Meloxicam | Meloxicam | 68 | 35 |
| Xarelto | Rivaroxaban | 61 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | suppressed |
| Omeprazole | Omeprazole | 56 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 25 |
| Linzess | Linaclotide | 48 | 15 |
| Januvia | Sitagliptin Phosphate | 46 | 15 |
| Digoxin | Digoxin | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 14 |
| Glimepiride | Glimepiride | 39 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 12 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Simvastatin | Simvastatin | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Prolia | Denosumab | 20 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 18 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Prednisone | Prednisone | 17 | 14 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Colchicine | Colchicine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Lidocaine | Lidocaine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Chloroquine Phosphate | Chloroquine Phosphate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.85 · 35 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Cologuard Collection Kit, ENTRESTO, EVENITY, JARDIANCE, LEQVIO, REZDIFFRA, VOQUEZNA, XIFAXAN, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error